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Abstract. In clinical trials within lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH-LUTS), the International Prostate Symptom Score (IPSS) is commonly
the primary efficacy outcome while the Quality of Life (QoL) score and the BPH Impact
Index (BII) are common secondary efficacy markers. The current study aimed to characterize
BPH-LUTS progression using responses to the IPSS, the QoL, and the BII in an integrated
item response theory (IRT) framework and assess the Fisher information of each scale. The
power of this approach to detect a drug effect was compared with an IRT approach
considering only IPSS responses. A unidimensional and a bidimensional pharmacometric
IRT model, based on item-level IPSS responses in a clinical trial with 403 patients, were
extended by incorporating patients’ QoL and summary BII scores over the 6-month trial
period. In the developed unidimensional integrated model, the QoL score was found to be
the most informative, representing 17% of the total Fisher information, while the combined
information content of the seven IPSS items represented 70.6%. In the bidimensional model,
“storage” and both storage and “voiding” disability drove QoL and summary BII responses,
respectively. Sample size reduction of 16% to detect a drug effect at 80% power was obtained
with the unidimensional integrated IRT model compared with its counterpart IPSS IRT
model. This study shows that utilizing the information content across the IPSS, QoL, and BII
scales in an integrated IRT framework results in a modest but meaningful increase in power
to detect a drug effect.
KEY WORDS: BPH; BPH Impact Index; Item Response Theory; International Prostate Symptom
Score; LUTS; Quality of Life.
INTRODUCTION
As the prostate enlarges with age, older men may suffer
from the obstruction of the prostatic urethra and deteriora-
tion of the urethral sphincter function (1). This condition is
known as benign prostate hyperplasia (BPH) and is estimated
to affect 50% of the male population by age 60 years (2,3).
Lower urinary tract symptoms (LUTS) often develop due to
BPH and are thought to stem from a combination of both
static and dynamic factors of BPH as well as the bladder’s
response to outflow obstruction (4,5). The prevalence of
BPH-LUTS is similar across different countries (6–11) and
can hence be considered a medical condition with a substan-
tial impact on public health globally speaking.
To assess BPH-LUTS, which, in addition to urinary
function, may impact patients’ general well-being as well as
different facets of their everyday life, three validated, disease-
specific, patient-reported outcomes (PROs) are convention-
ally used. The International Prostate Symptom Score (IPSS)
(also called as the American Urological Association Symp-
tom index) (12) is the most widely used PRO within BPH-
LUTS (13,14) and consists of seven items that each can be
rated from zero to five. IPSS voiding items describe the
severity of a feeling of incomplete emptying of the bladder
following urination, urination intermittency, the urgency to
urinate, the weakness of the urinary stream, and straining
during urination. IPSS storage items describe urination
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frequency, the urgency to urinate, and nocturia (15). Current
versions of the IPSS questionnaire include an additional
question following the seven IPSS items, known as the
Quality of Life (QoL) or “bother” question (16). The QoL
question assesses a patient’s perception of his current health
state by asking how he would feel if he were to spend the rest
of his life with his urinary condition. It can be rated from zero
to six, zero corresponding to “Delighted” and six to
“Terrible.” Lastly, the BPH Impact Index (BII) (17) is a
four-item questionnaire that assesses the physical discomfort
associated with urinary problems, the degree of worrying
regarding health due to urinary problems, the perception of
overall bother associated with urination, and the hindering of
performance of desired activities due to urinary problems.
Three of the BII items are rated from zero to three while one
is rated from zero to four, resulting in a summary BII ranging
from zero to 13.
In clinical trials investigating treatment of BPH-LUTS,
the summary IPSS is conventionally specified as the primary
efficacy outcome measure, while the QoL and summary BII
are specified as secondary efficacy markers (13). These three
scales may contribute different insights into BPH-LUTS, and
it may hence be of value to regard the information of these
scales jointly rather than separately to more precisely
determine the severity of BPH-LUTS in patients. Item
Response Theory (IRT) models can be used to incorporate
information from multiple PROs to assess the impact of a
given disease, giving higher weight to more sensitive PROs,
while still capturing information from less sensitive ones. As
its name suggests, IRT utilizes the item-level responses in
questionnaires to estimate an individual’s level of disability
(e.g., underlying BPH-LUTS), the sensitivity of each item to
change in disability, and the thresholds of item scores along
the disability scale. Because IRT uses item-level data and
quantifies item sensitivity, an integrated IRT model regarding
information from the IPSS, QoL, and BII jointly may allow
for a powerful approach for assessing BPH-LUTS and
detecting drug effects. IRT analyses combining information
from different scales have been performed within the
therapeutic areas of neonatal pain (18,19) and migraine
(20), but, to date, not within BPH-LUTS.
Building on a recent pharmacometric IRT model based
on item-level IPSS data in a clinical trial with the GnRH
antagonist degarelix (21), the current study aims to charac-
terize BPH-LUTS progression by joint analysis of item-level
IPSS, the QoL score, and BII data in an integrated IRT
framework while assessing the informativeness of each scale.
The power of this integrated BPH-LUTS IRT model to detect
a drug effect will be compared with the longitudinal IRT
model considering only IPSS responses.
METHODS
Data
Data from Ferring Pharmaceuticals A/S trial CS36
(NCT00947882) was utilized in the current work, which was
also used for the development of a previous longitudinal IPSS
IRT model (21). CS36 was a Phase II placebo-controlled,
double-blind, parallel-group, randomized dose-finding study,
where a single subcutaneous injection of either 10, 20, or
30 mg of the GnRH antagonist degarelix 40 mg/mL solution
was administered to patients. The trial enrolled 403 patients
with an IPSS ≥ 13 and a QoL score ≥ 3 at the screening visit
2 weeks before dosing at baseline. Over the 6-month trial
period, eight visits were planned (a baseline visit and 14 days
and 1, 2, 3, 4, 5, and 6 months after dosing). Item-level IPSS
and the QoL score were assessed at each of these visits, while
the summary BII (BIIsummary) was assessed at three visits
(baseline visit and 3 and 6 months after dosing). Due to the
unavailability of item-level BII responses, the BIIsummary was
considered an item with 14 possible categories.
Item Response Theory Analysis
Psychometrically, regarding the IPSS as either unidimen-
sional or bidimensional is valid based on multiple studies
within BPH-LUTS (21–23). Building on this prior knowledge,
both unidimensional and multidimensional integrated IRT
approaches were investigated in the current work.
Unidimensional Item Response Theory Modeling
A unidimensional IRT model was first fit to the data
assuming a single latent construct driving patients’ responses
to the IPSS, QoL, and BIIsummary. Data from all individuals
and all visits were used to estimate the item characteristic
curves (ICCs) (24–27) (termed the IDVIS approach (21)).
The reference baseline latent variable distribution(s) was
fixed to standard normal distributions N(0,1), and post-
baseline shift parameters were estimated to account for
differences in the distribution of latent disability following
intervention (placebo or treatment) while assuming that ICCs
are constant (24–27).
Each BPH-LUTS measure contains at least six item-
response categories (zero to five for the IPSS items, zero to
six for the QoL score, and zero to 13 for the BIIsummary item).
The probability of a patient answering at least k based on his
latent disability was described using a graded response model
(28):
P Yij≥k
  ¼ ea j ψi−b jkð Þ
1þ ea j ψi−b jkð Þ
where aj represents the slope/discrimination parameter of
item j, ψi the latent disability of patient i, and bj the difficulty/
location parameter of item j for category k. Cumulative
probabilities for an item with a score of maximum X were
modeled as:
P Yij ¼ 0
  ¼ 1−P Yij≥1 
P Yij ¼ k
  ¼ P Yij≥k −P Yij≥kþ 1 
P Yij ¼ X
  ¼ P Yij≥X 
where X is five for each of the seven IPSS items, six for the
QoL score, and 13 for the BIIsummary. Following ICC
estimation, the original individual assignment was reconciled
with the data, and the longitudinal model was combined with
the IRT ICC model to describe the relationship between
changes in disability over time and response probability.
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Multidimensional Item Response Theory Modeling
Factor analysis is an established statistical method for
informing the item structure of IRT models (29). It aims to
explain the correlation between items by assuming that one
or more latent variables (factors) steer responses to these
items. The factor loadings indicate the covariance between
each item and the factor(s) and allow for dimensionality
assessment. Factor analysis may be exploratory or confirma-
tory in nature: the former does not pre-specify the number of
factors to explore while the latter does. Building on the
bidimensional IRT model that regarded only item-level IPSS
(21), the item structure of an integrated multidimensional
IRT model was explored through confirmatory factor analysis
using two and three dimensions, respectively. Given that a
minimum of three items per latent variable is required to
preserve IRT model identification, no more than three latent
variables were explored in the current analysis. Varimax
orthogonal rotation (30) was used as the rotation method
during factor analysis. If an item was found to not be
predominantly correlated with a single factor, a compensatory
graded response model for polytomous data (31) was
implemented to allow multiple latent variables to affect the
probability of responses for this item. In the compensatory
graded response model, the probability of a patient answering
at least k for item j is:
P Yij≥k
  ¼ e am; jψm−Bk; jð Þ
1þ e am; jψm−Bk; jð Þ
with am; j  ψm ¼ a1; j  ψ1 þ a2; j  ψ2 þ…þ am; j  ψm
where m is the number of latent variables, ψm the vector of
latent disability estimates for patient i, aj the item-specific
discrimination parameters associated with each latent disabil-
ity, and Bk the overall difficulty of the item response category
k.
Calculation of Fisher Information Content
The Fisher information content of each item in the
unidimensional integrated IRT model was calculated as minus
the expectation of the second derivative of the log-likelihood.
The sensitivity of each item over the current study’s disability
range was visualized through their information functions.
Ranking of individual items was performed according to the
amount of information they contained relative to the total
information. This was achieved by calculating the area under
the curve for each item divided by the sum of all areas under
the curve. The unidimensional IRT model was used for
calculation of Fisher Information content as it allows for
comparison of the information content among all included
items based on the same common latent scale.
Longitudinal Modeling and Covariate Analysis
Longitudinal integrated IRT model development was
similar to that previously reported for longitudinal IRT
modeling based on IPSS data and readers are referred to
Lyauk et al. (21) for more details. Briefly, data from patients
receiving placebo treatment were first modeled to describe
the placebo effect, and subsequently, data from patients that
received degarelix were added to the dataset to describe the
drug effect. Following structural longitudinal model develop-
ment, baseline demographics (age, weight, and body mass
index), baseline physiological disease-specific measures (total
prostate volume, serum testosterone, prostate-specific anti-
gen, average flow rate, flow time including time to maximum
flow, maximum urine flow, post-void residual volume, voiding
time, and voiding volume), and study site region (North
America or Europe) were investigated as covariates. For this
purpose, a stepwise search (SCM) at a significance level of
0.01 in the forward inclusion step and 0.001 in the backward
elimination step. A multiplicative covariate model was used
for all parameters except those where the typical value was
expected to be zero or close to zero, such as baseline
disability. If this was the case, an additive covariate model
was used.
Software
NONMEM version 7.4.3 with the Laplacian method was
used for ICC estimation and longitudinal IRT modeling. Perl-
Speaks-NONMEM (32) (PsN) version 4.9.0 was used for
simulation-based model diagnostics, and the mirt package
version 1.31 in R 3.6.0 (33) was used for factor analyses and
to obtain initial estimates for ICC estimation in NONMEM.
Model Evaluation and Diagnostics
The goodness of fit of the ICCs was assessed using the
Empirical Bayes Estimate-based (26), as well as the sampling-
based (21), cross-validated generalized additive model
(GAM) cubic spline smooth. Longitudinal model selection
was based primarily on the change in objective function
(OFV) and secondly on assessment of visual predictive
checks (VPCs). For nested models, a difference in OFV
corresponding to a prespecified significance level (α = 0.05 for
everything but covariate analysis) was assumed statistically
significant assuming a χ2 distribution. For non-nested models,
the Akaike Information Criterion (AIC) was used. In
longitudinal IRT modeling, fixing the ICC parameters to the
values obtained in the ICC estimation step while estimating
the longitudinal parameters and simultaneously estimating
the ICCs and longitudinal parameters, respectively, was
investigated in terms of OFV reduction. VPCs were used to
assess the adequacy of the developed longitudinal models
using 200 samples.
Power Calculations
Power to detect a drug effect was determined by way of
clinical trial simulations with the respective final integrated
IRT models. The stochastic simulation and estimation (sse)
procedure in Perl-Speaks-NONMEM PsN (32) was used
specifying 1000 simulated data sets at four different sample
sizes while respecting the treatment to placebo allocation
ratio in the original CS36 data set. An initial Monte Carlo
Mapped Power (MCMP) procedure (34) informed the
determination of the sizes of these four data sets. No missing
item responses, as well as no dropout, was assumed in the
simulations. A threshold of 3.84 (p = 0.05) was used to
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identify significant reductions in OFV between the respective
full (estimating a drug effect) and reduced (not estimating a
drug effect) models. Type I error was investigated by
simulating 1000 data sets under each sample size from the
integrated IRT model with no drug effect. The proportion of
subsequent estimations where the drug effect was identified
as significant determined the type I error rate.
RESULTS
The CS36 trial enrolled 403 patients, of which 369
completed the six-month treatment period. The baseline
patient population characteristics have been presented else-
where (21). A total of 21,836 item-level IPSS, 3119 QoL
scores, and 1116 BIIsummary observations over the 6-month
trial period were available for analysis in the current work.
Figure 1 shows the mean time course for the total IPSS, the
QoL score, and the BII, respectively, in the CS36 trial. A
marked drop in mean score was observed for all treatment
arms on each BPH-LUTS scale and no dose-response
relationship was apparent on any of the three scales. The
Supplemental Material contains further details on the distri-
bution of responses in each BPH-LUTS scale.
Unidimensional Integrated Item Response Theory Modeling
The item characteristic curves (ICCs) for the seven IPSS
items, the QoL item, and the BIIsummary item in the
unidimensional integrated BPH-LUTS IRT model are shown
in Fig. 2, and the corresponding ICC parameter estimates are
shown in Table I. The latter were overall estimated with low
uncertainty, although higher uncertainty was observed for
BIIsummary difficulty parameters. The discrimination parame-
ter value was lowest for the Nocturia IPSS item (0.55) and
Fig. 1. Time course of the mean total International Prostate Symptom Score, Quality of
Life score, and summary Benign Prostatic Hyperplasia Impact Index. Standard errors are
indicated as error bars
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highest for the QoL item (1.22), indicating that they
respectively have the lowest and highest sensitivity to change
in disability. Adequate fit of the ICCs was observed with
GAM diagnostics and these are shown in the Supplemental
Material.
As shown in Fig. 3 and Table II, Fisher Information in
the unidimensional integrated BPH-LUTS IRT model ranged
from 3.7% for the IPSS Nocturia item to 17% for the QoL
item. The pooled information content of all IPSS items
represented 70.6% of the total information, the pooled
information of IPSS voiding items represented 44.7% of the
total information, and the pooled information of IPSS storage
items represented 25.8% of the total information (Table II).
Figure 4a illustrates the relationship between patients’
estimated latent disability in the unidimensional integrated
IRT model and their observed total IPSS, observed QoL
score, and observed BIIsummary, respectively. High level of
agreement was observed between latent disability and total
IPSS, QoL, and BIIsummary (Pearson correlation coefficients
of 0.96, 0.77, and 0.71, respectively), indicating that the
unidimensional IRT model’s estimate of underlying BPH-
LUTS is in line with the observed score from each BPH-
LUTS measure. Comparison of the change from baseline in
latent disability and the observed change from baseline in
each scale is shown in Fig. 4b. Based on the vast majority of
the illustrated data, a given patient with observed decreases
of at least three, one, and one in total IPSS, QoL, and
summary BII, respectively, is expected to have a decrease in
latent BPH-LUTS disability. Further specification of the
proportion of patients with decreased latent disability at each
observed score change is presented in the Supplemental
Material.
An exponential model with a drift component described
the longitudinal placebo effect and an offset effect described
the degarelix treatment effect, similar to the previous
longitudinal IRT model considering only IPSS responses (21):
Placebo ¼ Pmax 1−e− ln 2ð ÞTprogTime
 
þDrift  Time
Disability ¼ Baselineþ PlaceboþDrug
Drug ¼ 0 if dose ¼ 0 and Drug ¼ θ if dose > 0
and time > 0
with Baseline being the baseline disability, Pmax the maximal
placebo effect, Tprog the half-life to reach Pmax, Drift the
relapse/continued remission parameter, and Drug the offset
drug effect of degarelix estimated as a fixed effect (θ).
Between-subject variability (BSV) was implemented for
Baseline, Pmax, and Drift assuming a normal distribution
while BSV was implemented for Tprog assuming a lognormal
distribution. In agreement with the previous finding in the
IPSS IRT model (21), no dose-response or exposure-response
relationship was observed and such models (slope and Emax)
were not found to be significantly better than the effect of
degarelix modeled as independent of dose or exposure.
Estimation of the drug effect yielded a drop in objective
function of 25.0 compared with the reduced model where the
fixed effect parameter of degarelix treatment was fixed to
zero. Covariate relationships were investigated for the
Fig. 2. Item characteristic curves in the unidimensional integrated item response theory model. IPSS,
International Prostate Symptom Score; BPH, Benign Prostatic Hyperplasia
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Baseline, Pmax, and Drug parameters. Following backwards
elimination, post-void residual volume on Baseline disability
was found to be the only significant covariate (p < 0.001). The
final longitudinal model parameter estimates in the unidi-
mensional BPH-LUTS IRT model are presented in Table III
along with their relative standard errors. Categorical
VPCs for each item in the unidimensional integrated
IRT model are shown in the Supplemental Material,
showing adequate model fit for all nine items in all four
CS36 treatment arms.
Multidimensional Item Response Theory Modeling
Results of factor analyses with one and two dimensions,
respectively, are shown in Table IV. In the bi-dimensional
factor analysis, the IPSS storage items and the QoL score
were mainly reflected by one dimension while IPSS voiding
items were mainly reflected by the other dimension. More-
over, the BIIsummary item was found to be reflected by both
factors to an almost equal extent. Hence, a bidimensional
integrated IRT model was developed, where responses to
IPSS voiding items were driven by a “voiding” disability,
responses to IPSS storage items and the QoL score were
driven by a “storage” disability, and a compensatory graded
response model allowed for responses of BIIsummary to be
driven by both voiding and storage disability. The ICC
parameter estimates in the bi-dimensional integrated IRT
model are shown in Table I. Factor analysis using three
dimensions showed similar factor loadings to the two-
dimensional factor analysis, except for the Nocturia item
being mainly reflected by the third dimension. As at least
three items are needed per latent variable to preserve
identification, a three-dimensional IRT model was not
pursued.
Similar to the IPSS IRT model (21), a Weibull model was
used to describe the longitudinal placebo effect of the
underlying disability on each scale:
Placebo ¼ Pmax 1−e− ln 2ð ÞTprogTimeð Þ
WEI
 
þDrift  Time
Table I. Item Characteristic Curve Parameter Estimates in the
Integrated Unidimensional Lower Urinary Tract Symptoms Due to
Benign Prostatic Hyperplasia (BPH) Item Response Theory Model
Parameter Estimate Relative standard
error (%)
aIPSS1 1.19 7.3
bIPSS1,1 − 4.56 6
bIPSS1,2 2.02 7.3
bIPSS1,3 1.86 6.8
bIPSS1,4 1.57 7
bIPSS1,5 1.4 8.1
aIPSS2 1.04 6.8
bIPSS2,1 − 5.55 6
bIPSS2,2 2.65 7.3
bIPSS2,3 2.06 6.7
bIPSS2,4 1.49 7
bIPSS2,5 1.53 7.5
aIPSS3 1.04 7.5
bIPSS3,1 − 4.31 6
bIPSS3,2 2.09 7.4
bIPSS3,3 1.85 7.1
bIPSS3,4 1.23 7.5
bIPSS3,5 1.53 8.2
aIPSS4 0.929 6.9
bIPSS4,1 − 4.09 5.8
bIPSS4,2 2.14 7
bIPSS4,3 1.74 6.8
bIPSS4,4 1.26 7.4
bIPSS4,5 1.45 7.9
aIPSS5 0.972 7
bIPSS5,1 − 5.68 6.2
bIPSS5,2 2.56 7.7
bIPSS5,3 1.87 7
bIPSS5,4 1.45 7.1
bIPSS5,5 1.23 7.7
aIPSS6 0.774 8.1
bIPSS6,1 − 3.55 6.3
bIPSS6,2 2.01 8
bIPSS6,3 1.96 7.9
bIPSS6,4 1.96 8.6
bIPSS6,5 1.96 10.3
aIPSS7 0.549 7.6
bIPSS7,1 − 7.52 6.8
bIPSS7,2 4.79 7.9
bIPSS7,3 3.28 7.4
bIPSS7,4 2.26 8.1
bIPSS7,5 1.91 9.9
aQoL 1.22 6.4
bQoL1 − 7.26 6.3
bQoL,2 2.88 9.4
bQoL,3 1.97 6.8
bQoL,4 1.82 6.4
bQoL,5 1.38 6.7
bQoL,6 1.61 7.5
aBII 0.975 7.9
bBII,1 − 5.18 6.6
bBII,2 0.974 13.8
bBII,3 0.943 11.8
bBII,4 0.828 11.1
bBII,5 0.775 10.4
bBII,6 0.549 11.4
bBII,7 0.552 11.1
bBII,8 0.789 10
Table I. (continued)
Parameter Estimate Relative standard
error (%)
bBII,9 1.28 9.7
bBII,10 0.685 14.5
bBII,11 0.91 15.5
bBII,12 1.03 20.1
bBII,13 2.48 28.8
Post-baseline disability variance 2.59 6.3
Post-baseline disability mean − 1.53 5.9
Relative standard error was calculated as 100 * (standard error of
estimate / estimate). The typical value of η-shrinkage was 8.2%
a, discrimination parameters; b, difficulty parameters for each score
using the delta method (e.g., BIPSS1,2 0 bIPSS1,1 + bIPSS1,2); IPSS,
International Prostate Symptom Score; QoL, Quality of Life; BII,
Summary BPH Impact Index; IPSS1, incomplete emptying; IPSS2,
frequency; IPSS3, intermittency; IPSS4, urgency; IPSS5, weak
stream; IPSS6, straining; IPSS7, nocturia
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where WEI is the Weibull exponent. The drug effect model
consisted of separate offset effects on each latent variable
scale:
DisabilityVoiding ¼ BaselineVoiding þ PlaceboVoiding þDrugVoiding:
DisabilityStorage ¼ BaselineStorage þ PlaceboStorage þDrugStorage
The longitudinal bidimensional integrated model mini-
mized successfully and its parameter estimates are presented
in Table V. Due to model instability, it was not possible to
obtain parameter uncertainty through the covariance step or
perform covariate analysis. With the bidimensional model, a
drop in AIC of 2862.2 was observed compared with the
unidimensional integrated BPH-LUTS model. Categorical
VPCs for each item in the bidimensional integrated IRT
model with a compensatory graded response model for the
BIIsummary item are presented in the Supplemental Material.
Power Determination
Figure 5 shows the power of the integrated and IPSS IRT
models, respectively. Compared with the unidimensional IRT
model considering only IPSS data, the integrated unidimen-
sional IRT model displayed a sample size reduction of 16% to
detect a drug effect at 80% power (NIRT-IPSS-Unidimensional =
132 vs. NIRT-Integrated-Unidimensional = 111, well below the actual
trial size of 403 patients). At each sample size, the type I error
rate was found to be similar in both models (Supplemental
Material), and hence, no type-I error adjustment to the power
estimates was performed.
DISCUSSION
The current paper presents models integrating multiple
BPH-LUTS scales using IRT. To our knowledge, this is the
first model integrating several endpoints within the therapeu-
tic area. We investigated the information content within
different BPH-LUTS measures and compared the power to
detect a treatment effect of the integrated IRT approach with
a previously developed IRT models that considered only IPSS
responses. Assessing the effect of drugs on the voiding and
storage IPSS subscores is common practice in BPH-LUTS
clinical trials although its clinical meaningfulness is not
established (13,23,35–37). A previous longitudinal
bidimensional IRT model, based on item-level IPSS, aimed
to reflect this type of analysis while preserving item-level
information (21); in the current work, this model was further
extended by including data from the QoL and BII scales. This
allowed further characterization of underlying disability and
Fig. 3. Fisher Information Content of each International Prostate Symptom Score item, the Quality of life
score, and the summary Benign Prostatic Hyperplasia (BPH) Impact Index across the estimated disability in
the unidimensional integrated item response theory model. Shaded areas indicate the disability range for
95% of the study population
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differentiation of the effect of treatment on the “generalized”
voiding and storage latent variables, respectively.
In the unidimensional integrated BPH-LUTS IRT
model, all scales were modeled assuming a common
Table II. Fisher Information Content Ranking in the Unidimensional Integrated Item Response Theory Model
Item Item subscore category % of total Fisher information Cumulative % total
Quality of Life score – 17 17
IPSS1 Voiding 15.4 32.4
IPSS2 Storage 12.4 44.8
BIIsummary – 12.4 57.2
IPSS3 Voiding 11.9 69.1
IPSS5 Voiding 10.7 79.8
IPSS4 Storage 9.7 89.5
IPSS6 Voiding 6.8 96.3
IPSS7 Storage 3.7 100
IPSS, International Prostate Symptom Score; BIIsummary, Benign Prostatic Hyperplasia Impact Index sum of scores; IPSS1, incomplete
emptying; IPSS2, frequency; IPSS3, intermittency; IPSS4, urgency; IPSS5, weak stream; IPSS6, straining; IPSS7, nocturia
Fig. 4. a Disability estimated from the unidimensional integrated item response theory model vs. the
observed total International Prostate Symptom Score (IPSS), the observed Quality of Life (QoL) score, and
the observed summary Benign Prostatic Hyperplasia (BPH) Impact Index, respectively, b Change from
baseline in disability estimates from the unidimensional integrated item response theory model vs. observed
change from baseline in total IPSS, observed QoL score, and observed summary BPH Impact Index,
respectively, in 403 patients over the 6-month trial period
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underlying disability. Unidimensional IRT modeling allows
for determination of which item best describes latent
disability amongst all items in all BPH-LUTS scales. This
overall perspective is lost in a multidimensional IRT setting,
since here inference regarding information content can only
be made within each scale separately. This may explain why
other pharmacometric IRT studies have applied a unidimen-
sional modeling approach to analyze responses from multiple
scales (18–20). In the current unidimensional model, the QoL
item was found to be the overall most informative, contrib-
uting to 17% of the total information content, highlighting the
importance of this question for assessing BPH-LUTS. The
IPSS incomplete emptying item was the second-most informa-
tive item, yielding 15.4% of the total Fisher information. This
is in line with the previously presented unidimensional IPSS
IRT model, where the incomplete emptying item was found
to be the most informative (21). Approximately 70% of the
total information content was accounted for by the IPSS
items, confirming the importance of this scale in characteriz-
ing BPH-LUTS and supporting its common use as a primary
outcome measure in BPH-LUTS clinical trials. The higher
combined information content contribution of IPSS voiding
items compared with IPSS storage items is also in line with
results from the previous IPSS IRT analysis (21).
The minimal detectable difference (MDD) in observed
total IPSS has previously been reported as being at least three
points (17) and the current work supports this as decreases in
latent disability were strictly observed using this threshold (in
accordance with 99.9% of the data). However, as discussed in
previous work (21), decreases in latent disability may also be
obtained above the MDD, advocating the use of an IRT
approach rather than regarding only the summary IPSS to
assess patient’s underlying BPH-LUTS. For the QoL score, a
decrease of at least one point corresponds to predominantly
decreases in IRT-derived latent disability (in 96.8% of
patients as shown in the Supplemental Material). This is in
line with previous research, where mean QoL reductions
ranging 0.5 to 0.8 corresponded to perceived disease im-
provement in different groups of patients (38). Furthermore,
other authors have used a decrease in QoL score of one as
this represents a qualitative change on an ordinal scale (39).
The current findings may thus have implications for clinical
research and the assessment of drug efficacy within BPH-
LUTS based on the QoL score. A decrease of at least 0.5 BII
points (i.e., 1 point on the observed level) has been reported
as the MDD for this scale (17). The current results are in line
with this, as this to a large extent corresponds to decreases in
latent disability (in 93.6% of patients as shown in the
Supplemental Material).
The effect of post-void residual volume (PVR) on
baseline latent disability was the only covariate relationship
retained in the longitudinal unidimensional integrated IRT
model following the stepwise procedure. Weak correlation
between symptom severity as expressed by the IPSS and
physiologic measures, here amongst PVR, has been reported
(40). However, the current finding suggests that post-void
residual volume is indicative of underlying BPH-LUTS
severity as assessed by several disease-specific scales, and
further research should aim to confirm this finding.
Factor analysis with two dimensions indicated that IPSS
storage items and the QoL score were predominantly
correlated with the same dimension. This is supported by
the correlation between IPSS storage items and the QoL
score previously highlighted by other authors (15,41–43).
High correlation between the BIIsummary item and both the
storage as well as voiding disability was observed, and a
compensatory model was used to describe this finding. Each
individual BII item may be separately correlated with either
the storage or voiding disability, ultimately leading to the
BIIsummary reflecting this. Very limited research has to date
been performed examining the level of correlation between
individual IPSS and BII items (44), and these indicate that a
combination of IPSS voiding and storage items may correlate
with the BIIsummary. The compensatory model used in the
current work allows for a high value on either the voiding or
storage disability scale to potentially compensate for a low
value on the other scale, ultimately resulting in a high
probability of a BIIsummary score. It may be of interest to
investigate other within-item multidimensional models, such
as the non-compensatory/partially compensatory model (45),
Table III. Longitudinal Parameter Estimates for the Unidimensional Item Response Theory (IRT) Model
Parameter Longitudinal unidimensional integrated IRT model
Value Relative standard error
Baseline − 0.0993 57.1
Pmax (maximal placebo response) − 1.22 9.2
Tprog (placebo half-life) 16.2 17.5
Drug effect − 0.565 19.3
Covariates
Post-void residual volume on baseline 0.00327 24.9
Interindividual variability (IIV)
IIV Baseline 104.4% 5.5
IIV Pmax 134.9% 13.9
IIV Drift 0.9% 9
IIV Tprog 51.7% 12.6
IIV Baseline-Pmax correlation 15.5% 46.3
IIV Pmax-Drift correlation 45.4% 36.5
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where high disability on both scales is needed to obtain a high
score probability. Due to its complexity and requirement of a
larger number of parameters (separate difficulty parameters
on each scale), this type of within-item multidimensionality
was not investigated in the current work. Compared with a
longitudinal bi-dimensional integrated IRT model solely
attributing the BIIsummary item to the voiding latent variable,
the compensatory model yielded a drop in AIC of 54.9 points
(data not shown).
Incorporating longitudinal QoL and BII scores along
with longitudinal item-level IPSS responses in the
pharmacometric IRT framework reduced the sample size by
16% to detect a drug effect at 80% compared with
considering only item-level IPSS responses. This finding
showcases the benefit of utilizing all available information
from disease-specific scales within BPH-LUTS to assess
treatment effect in a clinical trial setting, made possible by
the IRT approach. Quantification of the increase in power to
detect a drug effect when simultaneously modeling all scale
endpoints as opposed to only considering the primary
endpoint marker has to our knowledge not been presented
within other therapeutic areas. It may therefore be of interest
to further investigate the power of the integrated IRT
approach in therapeutic areas where clinical trials commonly
include multiple disease-specific scales to assess the treatment
effect. The currently reported relative increase in power to
detect a drug effect with the integrated unidimensional IRT
model is expected to be similar within the context of
bidimensional IRT modeling, considering that the difference
in modeled data is the same (IPSS, QoL, and BII vs. only
IPSS). Although the longitudinal bidimensional integrated
IRT model yielded a much better fit in terms of likelihood, its
complexity and resulting instability may ultimately favor use
of the unidimensional approach, which also described the
data adequately. For these reasons, comparison of power
between the integrated and IPSS bidimensional model,
respectively, was not investigated in the current work. Lastly,
the observed total IPSS is the common primary endpoint
marker in BPH-LUTS clinical trials while pharmacometric
IRT focuses on latent disability as the estimand summary
measure (46). Pharmacometric IRT possesses higher power to
detect a drug effect compared with the total IPSS approach
(21), and hence the latter may not be meaningfully applied
when the sample size is determined based on IRT-derived
latent disability (using only item-level IPSS or multiple BPH-
LUTS scales, respectively).
A limitation of the current study is that item-level BII
scores were not available for analysis. The information
content of each individual BII item is likely to vary, whereas
only considering the summary score, as in the current study,
assumes it is the same. Accounting for this variation in
information content across BII items within the IRT frame-
work may further increase the characterization of BPH-
LUTS as well as the power to detect a drug effect of the
integrated IRT model. Incorporating summary-level score
Table IV. Factor Loadings Obtained from Confirmatory Factor Analysis (CFA) of the Nine Items Using One and Two Dimensions,
Respectively
Item Factor loadings using 1 factor Factor loadings using 2 factors
Factor 1 Factor 2
IPSS1 0.756 − 0.605 0.462
IPSS2 0.702 − 0.228 0.763
IPSS3 0.709 − 0.672 0.349
IPSS4 0.662 − 0.310 0.613
IPSS5 0.683 − 0.612 0.367
IPSS6 0.600 − 0.806 0.113
IPSS7 0.459 − 0.108 0.537
Quality of Life (QoL) 0.755 − 0.313 0.752
Summary BPH Impact Index (BIIsummary) 0.686 − 0.516 0.462
In the CFA with two factors, numbers in italic emphasize the largest factor loading value (covariance between each item and factor). Higher
factor loadings indicate closer association with the factor
IPSS1, incomplete emptying; IPSS2, frequency; IPSS3, intermittency; IPSS4, urgency; IPSS5, weak stream; IPSS6, straining; IPSS7, nocturia
Table V. Parameter Estimates of the Longitudinal Bidimensional
Integrated Item Response Theory Model
Parameter Value
BaselineV (voiding scale) − 0.0321
BaselineS (storage scale) − 0.0347
PmaxV (maximal placebo response voiding scale) − 0.939
PmaxS (maximal placebo response storage scale) − 1.36
TprogV (placebo half-life voiding scale) 12.3
TprogS (placebo half-life storage scale) 14
Weibull shape parameter (common for both scales) 1.6
Drug effect voiding scale − 0.369
Drug effect storage scale − 0.634
Interindividual variability (IIV)
IIV Baselinev (voiding scale) 98.6%
IIV BaselineS (storage scale) 128.1%
IIV Baselinev-BaselineS correlation 28.9%
IIV Pmax (common for both scales) 114.9%
IIV Tprog (common for both scales) 60.8%
IIV Drift (common for both scales) 0.6%
IIV Pmax-Drift correlation 33.2%
Interindividual variability was assumed normally distributed for the
Baseline, Pmax, and Drift parameters and lognormally distributed for
the Tprog parameter. No relative standard errors were computed due
to model stability issues
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data as an item, when item-level data are not available, has
been reported previously in integrated IRT modeling (19).
Although inferior compared with analyzing item-level BII
scores, ignoring the BIIsummary data will lead to a loss of
information, as shown by its Fisher Information content
contribution in the unidimensional integrated IRT model
(Table II). Further, the BIIsummary was assessed at three visits
(baseline, 3 months post-dose, and 6 months post-dose) while
item-level IPSS and the QoL score were measured at eight
visits. The lower number of BIIsummary observations may
explain the overall higher uncertainty of BIIsummary difficulty
parameters compared with those estimated for individual
IPSS items and the QoL score. Moreover, similar to the
longitudinal bidimensional IRT model based on item-level
IPSS (21) as well as other multidimensional pharmacometric
IRT models (24,25), the complexity of the longitudinal
bidimensional integrated IRT model led to instability issues.
It was hence not possible to obtain the uncertainty of
longitudinal parameters or perform covariate analysis for this
model. For the same reason, simultaneous estimation of ICCs
and longitudinal parameters was not possible. More advanced
and time-consuming techniques such as the bootstrap may be
used to obtain parameter precision but was not performed
here. The longitudinal bidimensional integrated IRT model
minimized succesfully and showed adequate item and
summary-level data description as assessed through VPCs;
the longitudinal parameters were therefore ultimately
deemed trustworthy. Lastly, in the longitudinal unidimen-
sional integrated IRT model, simultaneously estimating the
ICCs and longitudinal parameters decreased the objective
function value by 16.7 points (data not shown) compared with
fixing the ICCs. This was not significant given 63 degrees of
freedom (63 ICC parameters) under a χ2 distribution.
Although validated to assess BPH-LUTS (16,17,47),
neither the IPSS, the QoL score, or the BII assesses
incontinence, which may be an important and bothersome
symptom in patients with BPH-LUTS (14,48). Extending the
current models to include such information using, e.g., the
Incontinence Severity Index (49), the Epidemiology of LUTS
questionnaire (50), and/or the International Consultation on
Incontinence Modular Questionnaire (51) may further en-
hance the characterization of BPH-LUTS and its progression
as well as further increase the power to detect a drug effect
compared with only regarding the IPSS. In this context, it
may also be of benefit to investigate the inclusion of generic
PROs such as, e.g., the EuroQol-5 Domain scale (52) (EQ-
5D) and the Visual Analogue Scale (53,54), potentially while
guiding responses from these scales towards BPH-LUTS
using a supervised IRT approach (55,56).
CONCLUSION
IRT modeling was used to integrate data from multiple
disease-specific PRO endpoints within BPH-LUTS into a
Fig. 5. Power curves for the unidimensional integrated and the unidimensional International Prostate Symptom Score
(IPSS) item response theory pharmacometric models, respectively, using a stochastic simulation and estimation procedure.
One thousand simulated data sets from the integrated unidimensional item response theory model at sample sizes of 33, 66,
99, and 137 patients were used for model estimation with the respective full (with a drug effect parameter) and reduced
(without a drug effect parameter) models. Vertical lines indicate the 95% confidence interval for the calculated power
estimates. A decrease of 3.84 was used to establish significant improvement in objective function between the full and
reduced models of the respective approaches
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single model. A sample size reduction of 16% to detect a drug
effect at 80% power was obtained with the unidimensional
integrated IRT model compared with its counterpart IPSS
IRT model. This study shows that utilizing the information
content across IPSS, QoL, and BII scales in an integrated IRT
framework results in a modest but meaningful increase in
power to detect a drug effect.
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